Spectrum Pharma Says U.S. FDA Rejects Its Bladder Cancer Drug Spectrum Pharma Says U.S. FDA Rejects Its Bladder Cancer Drug
Spectrum Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration had rejected the drugmaker ' s bladder cancer treatment, apaziquone.Reuters Health Information
Source: Medscape Urology Headlines - Category: Urology & Nephrology Tags: Hematology-Oncology News Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Hematology | Pharmaceuticals | Urology & Nephrology